Chemicals and healthcare group Bayer AG is poised to announce the acquisition of U.S. seeds company Monsanto Co on Wednesday for more than $66 billion, clinching the biggest deal of the year, people familiar with the matter said.
By accepting Bayer’s offer, the largest cash acquisition proposal on record, Monsanto is set to give the German company a shot at grabbing the top spot in the fast-consolidating farm supplies industry, combining its crop science business with Monsanto’s strength in seeds. It will also set the stage for the deal to be closely scrutinized by antitrust regulators.
The breakthrough in negotiations, which follows more than four months of talks, came after Bayer further improved on the sweetened offer of $127.50 per share in cash it disclosed last week, the people said.
However, the deal will still value Monsanto at less than $130 per share, which the company was previously hoping to fetch, the people added.
Once St. Louis, Missouri-based Monsanto’s board of directors approves the deal on Tuesday, Leverkusen-based Bayer’s supervisory board will meet on Wednesday to also authorize the transaction, with an announcement expected before the stock market opens in New York on Wednesday, some of the people said.
It is still possible the board of either company could decide to walk away from the deal at the last minute, the people cautioned.
The sources asked not to be identified because the deliberations are confidential. Bayer and Monsanto declined to comment.
Monsanto’s shares ended 0.8 percent lower at $106.10 in New York on Tuesday amid uncertainty over whether any agreed deal will clear antitrust hurdles. The stock later climbed to $108.79 in after-hours trading. Bayer shares ended trading in Frankfurt down 0.3 percent at 93.3 euros.
Bayer said last week talks with Monsanto had advanced and that it was willing to offer $127.50 per share, up from $125 previously, valuing Monsanto at more than $65 billion, including debt.
Sources told Reuters that topping up the price secured Bayer access to more privileged information on Monsanto’s business performance and paved the way for more detailed negotiations.
“Given recent updates on the Monsanto approach suggest a final conclusion may be close, we suspect (Bayer) will work hard to try and reach a final conclusion before the Meet Management event, if possible,” Jefferies Research analyst Jeffrey Wolford said in a research note before the news, referring to Bayer’s presentations day for analysts and investors in Cologne next Tuesday.
Bayer’s bid to combine its crop chemicals business, the world’s second-largest after Syngenta AG, with Monsanto’s industry leading seeds business, is the latest in a series of major consolidation moves in the agrochemical sector.
U.S. chemicals giants Dow Chemical and DuPont have agreed to merge and spin off their respective seeds and crop chemicals operations into a major agribusiness.
Syngenta last year fought off unwanted suitor Monsanto, only to later agree to a takeover by ChemChina.
(Reporting by Arno Schuetze and Greg Roumeliotis; Additional reporting by Oliver Hirt in Zurich and Patricia Weiss and Ludwig Burger in Frankfurt; editing by Greg Mahlich and Andrew Hay)
Shock after Trump mused about taking insulin in White House event: ‘What does he have to lose?’
During a press conference today, President Trump rattled off a statement that left quiet a few people once again scratching their heads.
"I don't use insulin. Should I be? Huh?" Trump said. "I never thought about it. But I know a lot of people are very badly affected, right? Unbelievable."
As expected, many of Trump's critics on Twitter wondered what he was talking about.
I support free will. Let him take as many drugs as he wants. I mean, what does he have to lose?
WATCH: Trump wonders if he should start taking insulin
On Tuesday, at a press conference, President Donald Trump mused aloud whether he should start taking insulin.
"I don’t use insulin. Should I be? Huh? I never thought about it," he said.
"But I know a lot of people are very badly affected, right?" he added a second later. "Unbelievable."
Insulin is a crucial hormone the regulates blood sugar. People who are afflicted with Type 1 diabetes are incapable of producing it in their pancreas, and thus must administer it to themselves regularly through injections or pumps.
Trump muses about using insulin just for fun pic.twitter.com/PWvEhEcmTM
‘Exonerated Five’ member warns of a ‘dangerous time’ after latest Central Park incident
On CNN Tuesday, Yusef Salaam, one of the members of the Exonerated Five, warned about the implications of recent racist incidents to the state of civil rights in America.
"I want to ask you, in the course of the last couple of days we've covered this story, we've covered the story of a man who died after police put him in a hold with a knee to the neck. Yesterday I spoke with an African-American journalist who covered the Kentucky governor being hung in effigy, with people doing it who didn't seem to understand why that was problematic," said anchor Brianna Keilar. "And I just wonder what that says to you, after all of these decades, about where the country is."